In September 2021, Soaring Eagle Acquisition merged with Ginkgo Bioworks, and the company was delisted from the stock market. Soaring Eagle now essentially trades under the Ginkgo Bioworks label.
The SPAC merger resonates having Ginkgo Bioworks maintaining its current management team, but Soaring Eagle’s CEO Harry Sloan joins the company’s Board. Also several members of Soaring Eagle have also taken prominent positions in the newly merged company.
Ginkgo Bioworks Holdings Stock Analysis:
Based on the Ginkgo Bioworks Holdings stock forecasts from 6 analysts, the average analyst target price for Ginkgo Bioworks Holdings is USD 8.44 over the next 12 months. Ginkgo Bioworks Holdings’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Ginkgo Bioworks Holdings is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Ginkgo Bioworks Holdings’s stock price was USD 3.23. Ginkgo Bioworks Holdings’s stock price has changed by +35.71% over the past week, +14.54% over the past month and 0% over the last year.
Recent Analyst Ratings:
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
||Maintains||Jefferies Financial LLC||
USD 11.5 » USD 4.35
||Target Down||BTIG Research||
||Downgraded by||Bank of America Securities||
||Maintains||Raymond James Capital||
||Target Lowered by||Raymond James Capital||
USD 14.5 » USD 11.5
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What we don’t like:
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector